Rationale for combined therapies in severe-to-critical COVID-19 patients.

Autor:	Gonzaga A; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Institute of Bioengineering, Miguel Hernández University, Elche, Spain., Andreu E; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Applied Physics Department, Miguel Hernández University, Elche, Spain., Hernández-Blasco LM; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Meseguer R; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Clinic University Hospital, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA) Health Research Institute, Valencia, Spain., Al-Akioui-Sanz K; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain., Soria-Juan B; Réseau Hospitalier Neuchâtelois, Hôpital Pourtalès, Neuchâtel, Switzerland., Sanjuan-Gimenez JC; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Ferreras C; Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain., Tejedo JR; Department of Molecular Biology and Biochemical Engineering, University Pablo de Olavide, Seville, Spain.; Biomedical Research Network for Diabetes and Related Metabolic Diseases-Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) of the Carlos III Health Institute (ISCIII), Madrid, Spain., Lopez-Lluch G; University Pablo de Olavide, Centro Andaluz de Biología del Desarrollo - Consejo Superior de Investigaciones Científicas (CABD-CSIC), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Sevilla, Spain., Goterris R; Clinic University Hospital, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA) Health Research Institute, Valencia, Spain., Maciá L; Nursing Department, University of Alicante, Alicante, Spain., Sempere-Ortells JM; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Biotechnology Department, University of Alicante, Alicante, Spain., Hmadcha A; Department of Molecular Biology and Biochemical Engineering, University Pablo de Olavide, Seville, Spain.; Biosanitary Research Institute (IIB-VIU), Valencian International University (VIU), Valencia, Spain., Borobia A; Clinical Pharmacology Department, La Paz University Hospital, School of Medicine, Universidad Autónoma de Madrid, IdiPAz, Madrid, Spain., Vicario JL; Transfusion Center of the Autonomous Community of Madrid, Madrid, Spain., Bonora A; Health Research Institute Hospital La Fe, Valencia, Spain., Aguilar-Gallardo C; Health Research Institute Hospital La Fe, Valencia, Spain., Poveda JL; Health Research Institute Hospital La Fe, Valencia, Spain., Arbona C; Valencian Community Blood Transfusion Center, Valencia, Spain., Alenda C; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Tarín F; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Marco FM; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Immunology Department, Dr. Balmis General University Hospital, Alicante, Spain., Merino E; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Department of Clinical Medicine, Miguel Hernández University, Elche, Spain.; Infectious Diseases Unit, Dr. Balmis General University Hospital, Alicante, Spain., Jaime F; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Ferreres J; Intensive Care Service, Hospital Clinico Universitario, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA), Valencia, Spain., Figueira JC; Intensive Care Unit, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain., Cañada-Illana C; Emergency Department, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain., Querol S; Banc de Sang I Teixits, Barcelona, Spain., Guerreiro M; Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Eguizabal C; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Galdakao, Spain.; Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain., Martín-Quirós A; Emergency Department, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain., Robles-Marhuenda Á; Internal Medicine Department, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain., Pérez-Martínez A; Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain.; Department of Pediatrics, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain., Solano C; Hematology Service, Hospital Clínico Universitario, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA), Valencia, Spain., Soria B; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Institute of Bioengineering, Miguel Hernández University, Elche, Spain.; Biomedical Research Network for Diabetes and Related Metabolic Diseases-Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) of the Carlos III Health Institute (ISCIII), Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 Sep 11; Vol. 14, pp. 1232472. Date of Electronic Publication: 2023 Sep 11 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1232472
Abstrakt:	An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19's pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients. Competing Interests: AP-M, CF and BS filed patents on this topic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Gonzaga, Andreu, Hernández-Blasco, Meseguer, Al-Akioui-Sanz, Soria-Juan, Sanjuan-Gimenez, Ferreras, Tejedo, Lopez-Lluch, Goterris, Maciá, Sempere-Ortells, Hmadcha, Borobia, Vicario, Bonora, Aguilar-Gallardo, Poveda, Arbona, Alenda, Tarín, Marco, Merino, Jaime, Ferreres, Figueira, Cañada-Illana, Querol, Guerreiro, Eguizabal, Martín-Quirós, Robles-Marhuenda, Pérez-Martínez, Solano and Soria.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu